Truist analyst Peter Osterland raised the firm’s price target on Chemours (CC) to $30 from $27 and keeps a Buy rating on the shares. As the Iran conflict continues to disrupt commodity pricing and regional logistics, the firm continues to view Chemours’ geographic footprint within titanium dioxide as “relatively advantaged” compared to Chinese and Western competitors, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC:
- Chemours price target raised to $26 from $21 at RBC Capital
- Chemours price target raised to $29 from $23 at UBS
- Chemours price target raised to $27 from $21 at Truist
- Chemours price target raised to $25 from $21 at Mizuho
- Neutral Outlook on Chemours as Stable Thermal Performance Offsets Titanium Dioxide Uncertainty and Below‑Consensus 2026 EBITDA